Positive HERIZON-GEA-01 Ph 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted New SOC in 1L HER2+ve LA/M Gastroesophageal Adenocarcinoma November 24, 2025
Gedatolisib NDA submission to FDA in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer completed November 24, 2025
KaliVir Immunotherapeutics and Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors November 24, 2025
FDA grants accelerated approval to HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant NSCLC November 24, 2025
Gazyva® IV Infusion 1000 mg revised to allow combination therapy with the Venclexta® Tablets 10 mg, 50 mg, and 100 mg for 1L CD20-positive CLL/SLL November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop SC Formulation of Petosemtamab November 24, 2025
GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology November 24, 2025
Onco-Innovations Advances Optimization and Scale-Up of PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Ph 1 Clinical Studies November 24, 2025
Positive Recommendation from IDMC to Continue Pivotal Ph 3 ARTEMIA Trial Evaluating Tedopi® in NSCLC November 24, 2025
Statistical analysis of primary efficacy endpoints in Ph 2 trial conducted of MCS-8 (PCP) in prostate cancer completed November 24, 2025
Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML published in the Journal of Hematology & Oncology November 24, 2025
Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma November 24, 2025
FDA aligned on the design of pivotal study of pelareorep + SOC for 1L treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) November 24, 2025
FDA Accepts NDA for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC November 24, 2025
Rolling Submission of NDA to FDA initiated for Zipalertinib for Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations November 24, 2025
European Commission Approves Subcutaneous Administration of KEYTRUDA® for All Adult Indications Approved in the European Union November 24, 2025
FDA Approves KEYTRUDA® and KEYTRUDA QLEX™ (berahyaluronidase alfa-pmph formulation), Each with Padcev®, as Perioperative Treatment for Adults with Cisplatin-Ineligible MIBC November 24, 2025
